U Schaefer1, O Micke, P Schueller, N Willich. 1. Department of Radiation Oncology, Westfaelische Wilhelms University, Medical Center, Albert-Schweitzer-Strasse 33, D-48129 Muenster, Germany. uschafe@uni-muenster.de
Abstract
PURPOSE: To prospectively test the effectiveness of combined chemotherapy and radiation therapy for recurrent head and neck cancer. MATERIALS AND METHODS: In 32 patients, external-beam radiation therapy (2 Gy/d) was administered as a 5-day course with simultaneous hydroxyurea (1.5 g/d orally) and 5-fluorouracil (300 mg/m(2)/d bolus), followed by 9 days of rest. This cycle was repeated until a cumulative soft-tissue radiation dose of 110 Gy (including prior radiation therapy) was reached. RESULTS: At a median follow-up of 18 months, three patients were alive, and 29 had died. The overall 1-year survival rate was 39%. The overall response rate was 41% (13 patients). Acute toxicity was low. According to World Health Organization and Radiation Therapy Oncology Group criteria, there were three cases of grade 3 mucositis or dermatitis and three cases of grade 3 or 4 neutropenia. Three patients had grade 3 late effects: one oral trismus, one jugular venous thrombosis, and one cerebral stroke. CONCLUSION: The combination of simultaneous 5-fluorouracil and hydroxyurea infusion and local reirradiation is feasible for retreatment of recurrent head and neck tumors. This regimen provides short-term tumor control in most patients and long-term control in a few patients.
PURPOSE: To prospectively test the effectiveness of combined chemotherapy and radiation therapy for recurrent head and neck cancer. MATERIALS AND METHODS: In 32 patients, external-beam radiation therapy (2 Gy/d) was administered as a 5-day course with simultaneous hydroxyurea (1.5 g/d orally) and 5-fluorouracil (300 mg/m(2)/d bolus), followed by 9 days of rest. This cycle was repeated until a cumulative soft-tissue radiation dose of 110 Gy (including prior radiation therapy) was reached. RESULTS: At a median follow-up of 18 months, three patients were alive, and 29 had died. The overall 1-year survival rate was 39%. The overall response rate was 41% (13 patients). Acute toxicity was low. According to World Health Organization and Radiation Therapy Oncology Group criteria, there were three cases of grade 3 mucositis or dermatitis and three cases of grade 3 or 4 neutropenia. Three patients had grade 3 late effects: one oral trismus, one jugular venous thrombosis, and one cerebral stroke. CONCLUSION: The combination of simultaneous 5-fluorouracil and hydroxyurea infusion and local reirradiation is feasible for retreatment of recurrent head and neck tumors. This regimen provides short-term tumor control in most patients and long-term control in a few patients.
Authors: Aron Popovtzer; Iris Gluck; Douglas B Chepeha; Theodoros N Teknos; Jeffrey S Moyer; Mark E Prince; Carol R Bradford; Avraham Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-08 Impact factor: 7.038
Authors: Sophia C Kamran; Lauren C Harshman; Mandar S Bhagwat; Vinayak Muralidhar; Paul L Nguyen; Neil E Martin; Stephanie La Follette; Sarah Faso; Akila N Viswanathan; Jason A Efstathiou; Clair J Beard Journal: Adv Radiat Oncol Date: 2017-01-17
Authors: Carlos Suárez; Verónica Fernández-Alvarez; Marc Hamoir; William M Mendenhall; Primoz Strojan; Miquel Quer; Carl E Silver; Juan P Rodrigo; Alessandra Rinaldo; Alfio Ferlito Journal: Cancer Manag Res Date: 2018-11-13 Impact factor: 3.989
Authors: Kelly K Curtis; Helen J Ross; Ashley L Garrett; Theresa A Jizba; Ajay B Patel; Samir H Patel; William W Wong; Michele Y Halyard; Stephen J Ko; Heidi E Kosiorek; Robert L Foote Journal: Radiat Oncol Date: 2016-04-09 Impact factor: 3.481